Hexima Investor Updates
Hexima commences research into application of plant defensin technology in Candidaemias and Candida-based biofilms
Hexima is pleased to announce the commencement of a project to assess the application of Hexima’s antifungal technology in control of medically important Candidaemias and Candida-based biofilms. Systemic Candida infections are a major problem in immunocompromised...read more
Dear Shareholders I am pleased to inform you that the Hexima Rights Issue successfully closed last week with an overall take-up through entitlements and oversubscriptions of 65.4%. This result was very encouraging and Hexima is grateful to all shareholders who...read more
Hexima Limited ACN 079 319 314 (Company) wishes to advise shareholders that it is extending the invitation for shareholders to participate in the rights issue of 6 new shares for every 10 shares which shareholders held on the relevant record date (Offer), under the...read more
Hexima’s Annual Financial Report for the year ended 30 June 2016
Shares in Hexima Limited are not traded on the ASX. The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2016, was at the price of $0.20 per share.
Hexima Interim Financial Report for the 6 Months Ended 31 December